Peter J. Rosen

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

Daniel D. Von Hoff, Joseph J. Stephenson, Peter J. Rosen et al. · Journal of Clinical Oncology · 2010 · 643 citations

Medicine, Molecular Medicine, Oncology +17

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Ravi Vij, Michael Wang, Jonathan L. Kaufman et al. · Blood · 2012 · 254 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer

Howard I. Scher, Xiaoyu Jia, Kim Chi et al. · Journal of Clinical Oncology · 2011 · 250 citations · Full text

Medicine, Oncology, Pharmacology +16

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Mitesh J. Borad, Shantan Reddy, Nathan Bahary et al. · Journal of Clinical Oncology · 2014 · 191 citations · Full text

Pharmacy, Oncology, Pharmacology +17

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi et al. · Cancer · 2013 · 175 citations · Full text

Medicine, Hematology, Pharmacology +14